What question did this study set out to answer?

This study investigates how bridging therapy responses correlate with post-infusion efficacy and safety in Multiple Myeloma patients receiving ciltacabtagene autoleucel.

April 19, 2026SHILAP Revista de lepidopterologíaOpen Access

P36 | Effectiveness of Bridging Therapy Corresponds to Improved Outcomes After Ciltacabtagene Autoleucel: Phase 3 Cartitude-4 Study of Patients With Relapsed, Lenalidomide-Refractory Multiple Myeloma

View Full Paper

Ask AI

Bookmark

Authors

EZE ZamagniIstituto di Ematologia di Bologna BDB. DhakalMedical College of Wisconsin SIS. IidaNagoya City University

Discussion

Member takes

Implication

Phase 3 CARTITUDE-4 study shows improved outcomes in multiple myeloma with enhanced bridging therapy prior to ciltacabtagene autoleucel treatment, suggesting a vital strategy for patient care.

Key Points

This study investigates how bridging therapy responses correlate with post-infusion efficacy and safety in Multiple Myeloma patients receiving ciltacabtagene autoleucel.
Analyzed data from the CARTITUDE-4 trial with a median follow-up of 33.6 months.
Patients received apheresis, bridging therapy (either PVd or DPd), lymphodepletion, followed by cilta-cel infusion.
Evaluated responses based on progression-free survival (PFS) and overall survival (OS) post-treatment.
Among 196 patients, 172 (87.8%) received DPd, showing a significant improvement in both PFS and OS.
Thirty-month PFS rates were 75.9% for ≥VGPR and lower for others, while OS rates were 85.1% for ≥VGPR and dropped with poorer responses.
No movement or neurocognitive treatment-emergent adverse events (MNTs) were noted in ≥VGPR or PR groups, but higher risks were observed in patients with progressive disease.

Cite This Study

Zamagni et al. (2026) studied this question.

synapsesocial.com/papers/69e4702d010ef96374d8d69e https://doi.org/10.3324/haematol.2026.s2.14045

View Full Paper

Ask AI

Bookmark

Implication

Phase 3 CARTITUDE-4 study shows improved outcomes in multiple myeloma with enhanced bridging therapy prior to ciltacabtagene autoleucel treatment, suggesting a vital strategy for patient care.

P36 | Effectiveness of Bridging Therapy Corresponds to Improved Outcomes After Ciltacabtagene Autoleucel: Phase 3 Cartitude-4 Study of Patients With Relapsed, Lenalidomide-Refractory Multiple Myeloma

Discussion

Member takes

Implication

Key Points

Cite This Study

P36 | Effectiveness of Bridging Therapy Corresponds to Improved Outcomes After Ciltacabtagene Autoleucel: Phase 3 Cartitude-4 Study of Patients With Relapsed, Lenalidomide-Refractory Multiple Myeloma

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider